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ABSTRACT: The ﬁrst total synthesis of the potent and selective human
blood coagulation factor XIa inhibitor clavatadine A (1) is described. Direct,
early-stage guanidinylation enabled rapid, convergent access to an immediate
clavatadine A precursor. Concomitant lactone hydrolysis and guanidine
deprotection with aqueous acid cleanly provided clavatadine A (1) in only
four steps (longest linear sequence, 41−43% overall yield).

I

but still allow coagulation to occur.2 Further, because bleeding
associated with genetic FXIa deﬁciency (hemophilia C) is rarely
spontaneous and results only from signiﬁcant trauma, such as
major surgery or a car accident, treatment with a speciﬁc FXIa
inhibitor may not present an excessive bleeding risk like current
drugs on the market.2c Accordingly, clavatadine A (1) may
represent a lead compound in the development of the nextgeneration anticoagulant drug to treat thrombosis.
In conjunction with its intriguing biological activity,
clavatadine A (1) was an ideal template to probe the generality
of our early-stage guanidinylation approach for organic
synthesis.3 The retrosynthetic analysis of clavatadine A (1)
was also guided by a desire to construct the central carbamate
moiety in a convergent fashion in the key step. Before uniting
both halves of the molecule, however, it was sought to prepare
the terminal guanidine-containing, linear portion of clavatadine
A (1) by installing the guanidine moiety in the ﬁrst step. Direct
guanidinylation would obviate the circuitous approach conventionally used in synthesis to incorporate a terminal guanidine.
Namely, two unnecessary steps involving amine protecting
groups were eliminated by allowing a protected guanidinylation
reagent to react with a commercially available or readily
prepared primary amine rather than with an amine that had ﬁrst
been introduced as a latent amine precursor (azide,
phthalimide, etc.). A recent proof of concept study demonstrated that this strategy could be used successfully to prepare
the fully functionalized terminal guanidine-containing portion
of the indole alkaloids phidianidines A and B and ultimately led
to the total synthesis of these bioactive natural products.3

n 2008, after an extensive screen of over 38 000 biota
extracts for anticoagulant activity, Quinn and co-workers
reported the isolation of two new dibromophenol alkaloids,
clavatadines A (1) and B (2).1 These new alkaloids were
obtained from an extract of the marine sponge Suberea clavata
collected at Swain Reefs, Great Barrier Reef, Queensland,
Australia. Despite a relatively minor diﬀerence in the
functionality of these molecules, only clavatadine A (1) was
found to be a potent (IC50 = 1.3 μM) and selective inhibitor of
human blood coagulation factor XIa (FXIa). X-ray crystallographic studies revealed that precise placement of the linear,
arginine-like chain and the phenylacetic acid moiety at
opposing termini of clavatadine A (1) maximizes two key
noncovalent interactions within the FXIa active site.1

Our laboratory was drawn to clavatadine A (1) due to its
relative structural simplicity and noted activity toward a
promising new protein target in anticoagulant drug development. Recent studies suggest that targeted FXIa inhibition may
reduce the likelihood of excessive clot formation (thrombosis),
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Adopting this enabling and eﬃcient synthetic strategy to
prepare clavatadine A (1) in a similar fashion became necessary
after an advanced azide-containing intermediate could not be
converted into the primary amine needed to host the guanidine
found in clavatadine A (1).

Table 1. Bromination of Phenol 8

■

yield (%)a

RESULTS AND DISCUSSION
To explore whether a direct guanidinylation approach could be
used to prepare clavatadine A (1), the known4,5 N,N′-di-Bocprotected guanidine 5 was assembled by chemoselective
guanidinylation of 1,4-butanediamine (4) using Goodman’s
reagent6,7 (3) and Et3N under high dilution conditions
(Scheme 1). A modiﬁed isolation protocol combining an

entry

conditions

9

11

1b

(a) Br2, Et2O, rt, 2 h;
(b) 11, Br2, Et2O, rt, 6−8 h
8, Br2, Et2O, rt, 25 min
8, Br2, Et2O, rt, 6 h
NBS (2 equiv), p-TsOH, CH2Cl2, rt, 12 h
Br2, NaOAc, HOAc, rt, 7.25 h

0
70
0
0
21
68

85
0
90
96
12
11

2c
3c
4d
5c
a

Scheme 1. Synthesis of Clavatadine A (1)

Isolated yields of puriﬁed reaction products. bRef 11. cThis work.
Ref 15.

d

out the second bromination in a separate ﬂask.11 Subsequent
bromination of the resulting attenuated arene 11 to form 9 was
considerably slower (6−8 h) (Table 1, entry 1b).11 Results
from the present study conﬁrm these observations (Table 1,
entries 2 and 3). Even upon prolonged exposure (6 h) of a
solution of phenol 8 to excess Br2, the formation of compound
9 was never observed. In this instance, only monobrominated
phenol 11 was recovered, albeit in good yield (Table 1, entry
3).12 Without a base to neutralize the HBr generated during the
reaction, perhaps the strong Brønsted acid deactivated the
aromatic ring by protonating the hydroxy group to form an
oxonium ion.13 Strongly acidic solutions may also cause
hydrolytic cleavage of the benzofuranone ring, leading to
decomposition.14 A recent attempt by Lebouvier and coworkers to perform both bromination reactions in one ﬂask
using NBS and p-toluenesulfonic acid (p-TsOH) led to a
mixture of 9 and 11 in low yield (Table 1, entry 4); thus, a
more eﬃcient two-step, one-ﬂask method was desired.15
Accordingly, a slight excess of a weak base, sodium acetate,
was added to a solution of compound 8 and bromine that
neutralized both equivalents of HBr formed during the reaction
and led to the desired lactone 9 (Table 1, entry 5).16 This
improvement to the reported sequential11 and nonspeciﬁc15
bromination of homogentisic acid lactone (8) provided 4,6dibromohomogentisic acid lactone (9) in good yield.
Armed with an eﬃcient method to prepare both amine 5 and
lactone 9, the two halves were joined together to build the
complete clavatadine A (1) scaﬀold. In practice, exposure of
amine 5 to triphosgene aﬀorded the semistable isocyanate 6,
which was isolated in quantitative yield (Scheme 1).
Immediately, isocyanate 6 was added to a solution of lactone
9 and a catalytic amount of base to give the carbamate 10.17,18
Subsequent attempts to hydrolyze the lactone with aqueous
base followed by acidiﬁcation of the reaction mixture led only
to quantitative recovery of carbamate 10.19 It was then
discovered that addition of a solution of carbamate 10 to
dilute aqueous hydrochloric acid promoted hydrolysis of the
lactone and deprotected the di-Boc guanidine to provide
clavatadine A hydrochloride (1·HCl) in 93−96% yield.14
Analysis of the 1H NMR spectrum of unpuriﬁed, synthetic
clavatadine A (1) in DMSO-d6 revealed relatively few
impurities, but the spectrum did not precisely match the
reported spectrum of the natural product. There were two
prominent diﬀerences. First, the 1H NMR spectrum of
synthetic 1 lacked an apparent 1:1:1 triplet at approximately
δH 7.1 that was visible in the 1H NMR spectrum20 of natural 1,

aqueous NaHCO3 wash with subsequent column chromatography on silica gel was necessary to separate compound 5 from
excess diamine 4 and from the principal byproduct of the
reaction, triethylammonium triﬂuoromethanesulfonamide.
It was envisaged that the aromatic portion of clavatadine A
(1) could be prepared from the known homogentisic acid
lactone8 (8), which was prepared from commercially available
2,5-(dimethoxyphenyl)acetic acid (7).9,10 Ideally suited for the
present purposes, compound 8 cloaks the highly polar and
reactive o-hydroxyphenylacetic acid moiety as a lactone, thereby
facilitating handling of derivatives and enabling puriﬁcation by
silica gel chromatography. It also provides an activating,
ortho,para-directing hydroxy group that orchestrates regioselective installation of two bromine atoms: the ﬁrst bromine
adds ortho to the hydroxy at the most sterically accessible
position (C-6), and the second is introduced at a more
hindered location (C-4), but at a site that is also ortho to the
strongest activator, the hydroxy group.
Although dibromination of compound 8 has been explored,
prior eﬀorts have not addressed the need for an eﬃcient twostep, one-ﬂask method to prepare valuable synthetic
intermediate 9. For example, Krohn observed that regiospeciﬁc
monobromination of the electron-rich phenol 8 occurred
within 20−30 min when the reaction was conducted in diethyl
ether with Br2 to provide compound 11 in 85% yield (Table 1,
entry 1a).11 Even in the presence of excess bromine,
decomposition rather than the second bromination ensued if
the reaction mixture was left to stir for 2 days.11 To address this
problem, Krohn isolated bromophenol 11 by washing the
reaction mixture with aqueous sodium sulﬁte and then carried
121
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which was isolated by HPLC as its hydrotriﬂuoroacetate salt.1
This triplet is often observed in the 1H NMR spectrum of
natural compounds puriﬁed by HPLC when a dilute methanolic
or aqueous solution of triﬂuoroacetic acid is used as the eluent.
The sharp, spin 1 triplet (J ≈ 48 Hz) observed at δH 7.1 in the
natural sample likely arises from 1H coupling to 14N.1,21 Sharp
quadrupole coupling such as this is only observed in small,
symmetric molecules, not complex molecules such as
clavatadine A (1).22 Thus, the peak at δH 7.1 in the 1H NMR
spectrum of natural 1 is likely attributable to the presence of an
artifact: ammonium triﬂuoroacetate.21,22 Second, the singlet at
δH 6.51 in the 1H NMR spectrum of natural 1 is a common
impurity that appeared only in highly diluted samples in
DMSO-d6. Its presence was ascribed to the manufacturer of the
DMSO-d6 that was used to dissolve natural clavatadine A (1),
because the peak at δH 6.51 was no longer observed in 1H
NMR spectra after the supplier was changed. Aside from
impurities found only in the natural sample of 1, slight
diﬀerences were observed in the chemical shift values reported
for some NH and OH resonances in the synthetic sample:
carboxylic acid (δH 12.41 vs 12.38), phenol (δH 10.45 vs 10.42),
and guanidinium NH (δH 7.52 vs 7.45). Sample concentration
seemed to have the biggest impact on the observed 1H NMR
chemical shifts. Accordingly, the present data most closely
matched the reported values for the natural compound when
dilute solutions (1−2 mg/mL) of synthetic clavatadine A (1)
were prepared in DMSO-d6. Although the 400 MHz NMR
spectrometer used could not completely resolve the peaks at
approximately δH 3.1 (δH 3.11 and 3.08 for natural 1) or those
near δH 1.5 (δH 1.52 and 1.49 for natural 1), data gathered on a
600 MHz NMR instrument exhibited matching δH and J values
to the natural compound.1 All other 1D (13C and DEPT) and
2D NMR spectra of unpuriﬁed, synthetic clavatadine A (1)
were identical to those reported for natural 1. In addition, the
1
H NMR spectrum of synthetic clavatadine A (1) that had been
puriﬁed by HPLC to provide the corresponding hydrotriﬂuoroacetate salt (1·CF3CO2H) revealed coincidental
resonances with the natural material. The present preparation
of the title compound was further conﬁrmed by an FXIa
enzyme-inhibition assay, which revealed nearly identical IC50
values for the natural (1.3 μM)1 and synthetic (6.3 μM)
samples of clavatadine A (1) (Figure 1).

■

tion circumvented the cumbersome protected amine-to-amineto-guanidine sequence traditionally employed in the synthesis
of terminal guanidine-containing molecules and should enable
the rapid preparation of analogues for biological evaluation. It is
planned to use this basic approach to prepare clavatadine B (2)
and to synthesize non-natural analogues of clavatadine A (1) as
novel, reversible FXIa inhibitors.

■

EXPERIMENTAL SECTION

General Experimental Procedures. Infrared (IR) spectra were
obtained on neat solids or liquids using an ATR FT-IR spectrometer.
One- and two-dimensional 1H and 13C NMR spectra were recorded at
ambient temperature at 400 and 100 MHz, respectively, and calibrated
using tetramethylsilane at δ 0.00, unless otherwise stated. All chemical
shifts are reported in ppm on the δ scale, integration, multiplicity (br =
broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet,
or combinations thereof), and coupling constants in Hz. All 2D NMR
spectra were recorded in DMSO-d6. Carbon−hydrogen coupling
constant values in inverse-detection 2D NMR experiments, which
included gradient HSQC (1JCH = 140 Hz) and gradient HMBC (nJCH
= 8.3 Hz), matched those used in the clavatadine A (1) isolation paper
by Quinn and co-workers.1 Accurate mass (MS) measurements were
performed on an LCT premier time-of-ﬂight (TOF) instrument using
electrospray ionization in positive ion mode (ES+) by Dr. John
Greaves and Ms. Shirin Sorooshian. Liquid chromatography was
performed using variable forced air ﬂow (ﬂash chromatography) of the
indicated solvent system or solvent gradient through 60 Å silica gel
(SiO2) (40−63 μm, 230−400 mesh). Analytical thin-layer chromatography (TLC) was performed using 0.25 mm silica gel 60 (F254)
plates. Spots were visualized by short-wave (254 nm) UV irradiation
and/or by dipping the plates in phosphomolybdic acid (PMA), cerium
ammonium molybdate (CAM), ferric chloride, or ninhydrin solutions
followed by heating. All reaction mixtures not containing aqueous
reagents were carried out under an atmosphere of dry nitrogen using
standard syringe/septum techniques. Glassware was oven-dried
overnight at 130 °C, ﬂame-dried using a propane torch, and then
allowed to cool to ambient temperature under a stream of dry
nitrogen. Unless otherwise noted, all reagents were used as received
from commercial suppliers. Dichloromethane (CH2Cl2), tetrahydrofuran (THF), and Hünig’s base (i-Pr2NEt) were dried over anhydrous
CaH2 and distilled under N2. Triethylamine (Et3N) was dried over
KOH and distilled under N2. When anhydrous reaction conditions
were required, solvents were ﬁrst distilled under nitrogen onto
activated 3 Å molecular sieves and then were transferred under
nitrogen by cannula into amber-colored glass bottles for storage. These
bottles were capped with an Aldrich (St. Louis, MO, USA) Sure-Seal
PTFE disk and a metal crown cap using an Aldrich crown-cap crimper.
Factor XIa was purchased from Haematologic Technologies, Inc.
(Essex Junction, VT, USA), and substrate s2366 from Chromogenix
(manufactured by Instrumentation Laboratory, Bedford, MA, USA).
Clear 96-well Nunc microplates were purchased from Thermo
Scientiﬁc (Waltham, MA, USA). Absorbance was measured on a
PerkinElmer (Waltham, MA, USA) Envision 2104 multilabel reader.
N,N′-Di-Boc Guanidine 5. The known N,N′-di-Boc guanidine 5 was
prepared using an adaptation of the procedures of Botta and coworkers and Muñoz and co-workers.4,5 Spectroscopic data and copies
of spectra are also provided for compound 5 because complete data
have not yet been published. To a solution of 1,4-butanediamine (4)
(2.32 mL, 23.1 mmol, 3.0 equiv) in 320 mL of CH2Cl2 was added
Et3N (1.07 mL, 7.69 mmol, 1.0 equiv). Then, a solution of N,N′-diBoc-N″-triﬂylguanidine7 (3) (3.01 g, 7.69 mmol, 1.0 equiv) in 25 mL
of CH2Cl2 was added dropwise by addition funnel over approximately
1−2 h (the reaction mixture grew cloudy), and the reaction mixture
was stirred at ambient temperature for 12 h. After 12 h, the reaction
mixture was washed with saturated aqueous NaHCO3 (2 × 50 mL),
H2O (2 × 50 mL), and brine (1 × 50 mL), dried over anhydrous
Na2SO4, ﬁltered, and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography on silica gel (5:3:2 EtOAc−MeOH−Et3N)
aﬀorded the product as a pale yellow oil (2.49 g, 98%): IR (neat) νmax

CONCLUSIONS

In conclusion, the ﬁrst total synthesis of clavatadine A (1) has
been completed in four steps (longest linear sequence). The
overall yield of the convergent approach used was 41−43%
from commercially available compound 7. Direct guanidinyla-

Figure 1. Results of FXIa inhibition assay (IC50 6.3 μM) using
synthetic clavatadine A (1).
122
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and was concentrated in vacuo to provide a foamy, dark-browncolored solid (2.20 g, 110% mass balance, presuming i-Pr2NEt was
removed in vacuo). This solid was puriﬁed by ﬂash column
chromatography on silica gel (1:0 to 1:1 CH2Cl2−Et2O) to provide
carbamate 10 as a maroon-colored, foamy solid (1.36 g, 68% from
amine 5): IR (neat) νmax 3335, 2927, 1822, 1755, 1720, 1639, 1616,
1583, 1413, 1158, 733 cm−1; 1H NMR (CDCl3, 400 MHz) δ 11.48
(1H, br s), 8.40 (1H, apparent br t, J value indecipherable), 7.32 (1H,
s), 5.78 (1H, br t, J = 6.0 Hz), 3.69 (2H, s), 3.45 (2H, dt, J = 6.6, 6.0
Hz), 3.38 (2H, dt, J = 6.6, 6.0 Hz), 1.75−1.64 (4H, m), 1.50 (18H, s);
13
C NMR (CDCl3, 100 MHz) δ 171.3 (C), 163.5 (C), 156.3 (C),
153.3 (C), 152.3 (C), 151.7 (C), 142.7 (C), 125.5 (C), 118.3 (C),
115.0 (C), 114.4 (CH), 83.2 (C), 79.4 (C), 40.7 (CH2), 40.0 (CH2),
34.7 (CH2), 28.3 (CH3), 28.1 (CH3), 26.5 (CH2), 26.1 (CH2); 1H
NMR (DMSO-d6, 400 MHz) δ 11.51 (1H, br s), 8.32 (1H, apparent
br t, J value indecipherable), 8.13 (1H, t, J = 5.6 Hz), 7.66 (1H, s), 3.91
(2H, s), 3.28 (2H, m), 3.10 (2H, m), 1.58−1.50 (2H, m), 1.48 (9H, s,
and 2H, m), 1.40 (9H, s); 13C NMR (DMSO-d6, 100 MHz) δ 172.2
(C), 163.1 (C), 155.1 (C), 152.1 (C), 152.0 (C), 151.2 (C), 141.8
(C), 127.0 (C), 116.6 (C), 114.3 (C), 113.5 (CH), 82.8 (C), 78.0 (C),
40.1 (CH2), 39.4 (CH2), 34.7 (CH2), 27.9 (CH3), 27.5 (CH3), 26.5
(CH2), 25.8 (CH2); (+)-HRTOFESIMS m/z 685.0468 (calcd for
C24H3279Br2N4O8Na [M + Na]+, 685.0485); Rf = 0.36, 2:3 EtOAc−
hexanes, visualized with short-wave UV light, I2, and CAM/heat.
Clavatadine A (1). To a round-bottomed ﬂask charged with
carbamate 10 (1.205 g, 1.810 mmol) was successively added 12 mL of
THF and 48 mL of 1 M HCl(aq). The ﬂask was gently covered with a
glass stopper to prevent evaporation and to avoid plasticizer leaching
into the mixture, the latter of which occurred when a standard rubber
septum or plastic yellow cap was used to cover the aperture. The
resulting solution was heated at 30 °C (water bath) and stirred
vigorously for 20 h. After 20 h, the resulting suspension was vacuum
ﬁltered to remove 9 mg of a black-colored solid. The yellow-orangecolored ﬁltrate was then concentrated in vacuo to aﬀord clavatadine A
hydrochloride (1·HCl) as a peach-colored, amorphous solid (0.866 g,
93%). The 1H NMR chemical shifts for dilute solutions of synthetic
clavatadine A (1−2 mg of 1·HCl per milliliter of DMSO-d6) diﬀered
very slightly from those found in the previously reported 1H NMR
spectrum of natural clavatadine A hydrotriﬂuoroacetate (1·CF3CO2H)
(1.5 mg in DMSO-d6).1 All other NMR data, including 13C, DEPT135, and all correlations within gradient COSY, gradient HSQC, and
gradient HMBC spectra of unpuriﬁed synthetic clavatadine A (1),
matched previously reported spectra for natural clavatadine A (1):1 IR
(neat) νmax 3166, 2942, 1714, 1648, 1398, 1200, 953, 754 cm−1; 1H
NMR (DMSO-d6, 400 MHz, referenced to residual solvent peak at δ
2.50) δ 12.41 (1H, v br s), 10.45 (1H, s), 8.02 (1H, t, J = 5.6 Hz), 7.52
(1H, t, J = 5.6 Hz), 7.40−7.10 (2H, v br s), 7.10 (1H, s), 6.95−6.65
(2H, v br s), 3.66 (2H, s), 3.12 (2H, dt, J = 5.6, 5.6 Hz), 3.07 (2H, dt, J
= 5.6, 5.6 Hz), 1.50 (4H, m); 13C NMR (DMSO-d6, 100 MHz,
referenced to residual solvent peak at δ 39.50) δ 170.8 (C), 156.8 (C),
154.2 (C), 152.7 (C), 138.0 (C), 123.2 (C), 121.9 (C), 117.1 (DEPT135, CH), 115.7 (C), 40.4 (DEPT-135, CH2), 40.0 (DEPT-135, CH2),
35.4 (DEPT-135, CH2), 26.5 (DEPT-135, CH2), 25.8 (DEPT-135,
CH2); (+)-HRTOFESIMS m/z 480.9716 (calcd for C14H1979Br2N4O5
[M + H]+, 480.9722).
Puriﬁcation. An aliquot (4.0 mg) of synthetic clavatadine A
hydrochloride salt (1·HCl) was subjected to puriﬁcation by massdirected semipreparative HPLC to yield 3.4 mg of clavatadine A
hydrotriﬂuoroacetate (1·CF3CO2H) as a colorless oil (Agilent
Technologies (Santa Clara, CA, USA) 1200 system, G1311A pump,
G1315D diode array detector, Agilent 6120 quadrupole MS). HPLC
conditions: Zorbax C18 column (9.4 × 50 mm), ﬂow rate 5 mL/min,
solvent solvent A = 0.1% TFA in H2O, B = 0.1% TFA in CH3CN,
linear gradient from 95% solvent A, 5% solvent B to 5% solvent A, 95%
solvent B over 6 min, then to 95% solvent A, 5% solvent B in 2 min.
The oil was dissolved in DMSO to give a 10 mM stock solution.
Factor XIa Assay. Factor XIa enzyme (received as a 3.9 mg/mL
solution in glycerol−H2O, 1:1) was serially diluted to a working
concentration of 0.54 nM in assay buﬀer (pH 7.4 at rt) consisting of
50 mM Tris, 100 mM NaCl, 5 mM CaCl2, and 0.1 mg/mL BSA. The

3333, 2977, 2932, 1719, 1636, 1613, 1572, 1414, 1365, 1328, 1131,
1053 cm−1; 1H NMR (CDCl3, 400 MHz) δ 11.50 (1H, br s), 8.35
(1H, br s), 3.43 (2H, td, J = 7.2, 4.8 Hz), 2.74 (2H, t, J = 7.0 Hz), 1.63
(2H, m), 1.53 (2H, m), 1.51 (9H, s), 1.49 (9H, s); 13C NMR (CDCl3,
100 MHz) δ 163.6 (C), 156.1 (C), 153.3 (C), 83.1 (C), 79.3 (C), 41.8
(CH2), 40.7 (CH2), 30.8 (CH2), 28.3 (CH3), 28.1 (CH3), 26.4
(CH2); (+)-HRTOFESIMS m/z 353.2168 (calcd for C15H30N4O4Na
[M + Na]+, 353.2165); Rf = 0.39, 5:3:2 EtOAc−MeOH−Et3N.
6-Bromohomogentisic Acid Lactone (11). To a solution of
homogentisic acid lactone 8 (0.150 g, 1.00 mmol, 1.00 equiv)9,10 in
10 mL of Et2O was added bromine (0.154 mL, 3.00 mmol, 3.00 equiv)
dropwise by syringe. The reaction mixture was stirred at ambient
temperature for 25 min and then was poured into a separatory funnel
containing 10 mL of saturated aqueous Na2SO3. The layers were
separated, and the organic phase was washed with an additional 2 × 10
mL of saturated aqueous Na2SO3 and 1 × 10 mL of brine, dried over
anhydrous Na2SO4, ﬁltered, and concentrated in vacuo to provide the
product as a brown-colored solid (0.207 g, 90%): Rf of 11 = 0.34, 1:1
EtOAc−hexanes. Krohn ﬁrst reported this method to prepare
compound 11, but did not provide experimental details.11 Spectroscopic data for 11 match previously reported data for compound 6b
prepared by Lebouvier.15 If, instead, the above reaction mixture was
stirred at ambient temperature for 6 h, compound 11 was formed in
96% yield.
4,6-Dibromohomogentisic Acid Lactone (9). To a suspension of
homogentisic acid lactone 8 (0.601 g, 4.00 mmol, 1.00 equiv)9,10 and
sodium acetate (0.673 g, 8.20 mmol, 2.05 equiv) in 30 mL of acetic
acid was added a solution of bromine (0.62 mL, 12.0 mmol, 3.00
equiv) in 1.25 mL of acetic acid dropwise by syringe. The reaction
mixture was stirred at ambient temperature for 7 h, 15 min and then
was concentrated in vacuo to provide a brown solid (1.146 g). This
solid was dissolved in EtOAc, adsorbed onto 5 g of silica gel, and then
puriﬁed by ﬂash column chromatography on silica gel (1:4 EtOAc−
hexanes, to recover the desired product, compound 9, and then 1:1
EtOAc−hexanes to elute 6-bromohomogentisic acid lactone (11)).
This puriﬁcation provided the desired product, compound 9, as a
brownish-purple-colored powder (0.834 g, 68%, based on a theoretical
yield of 1.232 g, 4.00 mmol), and compound 11, as a brown-colored
powder (0.102 g, 11%, based upon a theoretical yield of 0.916 g, 4.00
mmol): Rf of 9 = 0.66, 1:1 EtOAc−hexanes. The spectroscopic data for
9 matched previously reported data for compound 6a prepared by
Lebouvier.15
N,N′-Di-Boc Guanidine-Containing Carbamate 10. To a cooled
(0 °C) solution of N,N′-di-Boc guanidine 5 (1.00 g, 3.03 mmol, 1.00
equiv) in 25 mL of CH2Cl2 was added triphosgene (0.297 g, 1.01
mmol, 0.33 equiv; CAUTION: highly toxic; open, weigh, and handle
only in a f ume hood and while wearing two pairs of nitrile gloves). Then, a
solution of saturated aqueous NaHCO3 (25 mL) was added, and the
biphasic reaction mixture was stirred vigorously at 0 °C for 30 min.
After 30 min, the reaction mixture was partitioned between 100 mL of
CH2Cl2 and 100 mL of H2O, the layers were separated, and the
aqueous layer was extracted with CH2Cl2 (3 × 15 mL). The combined
organic extracts were dried over anhydrous Na2SO4, ﬁltered, and
concentrated in vacuo to provide semistable, crude isocyanate 6 as a
light-brown-colored oil (1.11 g, 103% of theoretical). This oil was used
immediately in the next step without puriﬁcation. Diagnostic data: IR
(neat) νmax 3331, 2978, 2934, 2265, 1719, 1635, 1613, 1574, 1327,
1129, 731 cm−1; 1H NMR (CDCl3, 400 MHz) δ 11.50 (1H, br s), 8.36
(1H, br s), 3.46 (2H, m), 3.37 (2H, m), 1.67 (4H, m), 1.51 (9H, s),
1.50 (9H, s); 13C NMR (CDCl3, 100 MHz) δ 163.5 (C), 156.2 (C),
153.4 (C), 122.0 (NCO), 83.3 (C), 79.4 (C), 42.6 (CH2), 40.1 (CH2),
28.5 (CH2), 28.3 (CH3), 28.1 (CH3), 26.2 (CH2).
To a round-bottomed ﬂask containing a solution of dibromophenol
9 (0.933 g, 3.03 mmol, 1.00 equiv) and N,N-diisopropylethylamine
(0.103 mL, 0.606 mmol, 0.200 equiv) in 30 mL of CH2Cl2 was added
a solution of freshly prepared isocyanate 6 (1.11 g, 3.03 mmol, 1.00
equiv) in 30 mL of CH2Cl2 dropwise by cannula over 1 h. The ﬂask
containing isocyanate 6 was rinsed with CH2Cl2 (2 × 5 mL), and these
washings were added to the reaction ﬂask containing dibromophenol
9. The resulting solution was stirred at ambient temperature for 3 h
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(3) Buchanan, J. C.; Petersen, B. P.; Chamberland, S. Tetrahedron
Lett. 2013, 54, 6002−6004.
(4) Castagnolo, D.; Raffi, F.; Giorgi, G.; Botta, M. Eur. J. Org. Chem.
2009, 334−337.
(5) Expósito, A.; Fernández-Suárez, M.; Iglesias, T.; Muñoz, L.;
Riguera, R. J. Org. Chem. 2001, 66, 4206−4213.
(6) Feichtinger, K.; Zapf, C.; Sings, H. L.; Goodman, M. J. Org. Chem.
1998, 63, 3804−3805.
(7) Baker, T. J.; Tomioka, M.; Goodman, M. Organic Syntheses;
Wiley: New York, 2004; Coll. Vol. 10, pp 266−270.
(8) This compound, also known as 5-hydroxy-2(3H)-benzofuranone,
is commercially available but prohibitively expensive ($67.70/g, SigmaAldrich).
(9) Wolkowitz, H.; Dunn, M. S. Biochem. Prep. 1955, 4, 6−11.
(10) Abbott, L. D., Jr.; Smith, J. D. J. Biol. Chem. 1949, 179, 359−364.
(11) Krohn, K. Tetrahedron Lett. 1975, 52, 4667−4668.
(12) The spectroscopic data matched previously reported data for
this compound.
(13) The equilibrium constant for protonation of the hydroxy group
by HBr can be estimated by extrapolating pKa data of similar species.
For example, HBr, with a pKa of −9.0 (H2O), would likely protonate
the hydroxy group of homogentisic acid lactone with an approximate
equilibrium constant between 102.5 (methylphenyl ether (PhO+(H)
Me), pKa −6.5 (H2O)) and 106.8 (protonated methanol (MeO+H2,
pKa −2.2 (H2O)). Acidity constant data taken from the pKa table of
Prof. Dave Evans, which can be found at the following Web address:
http://evans.harvard.edu/pdf/evans_pka_table.pdf.
(14) Hillery, P. S.; Cohen, L. A. J. Org. Chem. 1983, 48, 3465−3471.
(15) Lebouvier, N.; Jullian, V.; Desvignes, I.; Maurel, S.; Parenty, A.;
Dorin-Semblat, D.; Doerig, C.; Sauvain, M.; Laurent, D. Mar. Drugs
2009, 7, 640−653.
(16) Cheng, J. F.; Nguyen, B. N.; Liu, X.; Lopaschuk, G. D.; Dyck, J.
R. U.S. Patent 7,696,365 B2, 2010.
(17) Wu, X.; Starnes, S. D. Org. Lett. 2012, 14, 3652−3655.
(18) Hlavácě k, J.; Pícha, J.; Vaněk, V.; Jirácě k, J.; Slaninová, J.; Fučík,
V.; Buděsí̌ nský, M.; Gilner, D.; Holz, R. C. Amino Acids 2010, 38,
1155−1164.
(19) The consumption of carbamate 10 under basic (0.1 M
NaOH(aq)) and reducing (0.21 M Na2SO3(aq)) conditions was
conﬁrmed qualitatively by TLC. In one experiment, in lieu of
acidiﬁcation, the reaction mixture was concentrated to provide a beigecolored solid. Analysis of the 1H NMR spectrum of the resulting
unstable compound, which decomposed upon exposure to air and
within hours in DMSO-d6 solution, revealed a highly shielded singlet
at δH 6.74 (1H, aromatic C−H) and a deshielded singlet at δH 3.99
(2H, benzylic CH2). In comparison, the aromatic C−H and benzylic
methylene resonances of synthetic 4,6-dibromohomogentisic acid,
which is similar to the hydrolysis product of compound 10, are δH 6.99
and 3.63, respectively, in DMSO-d6. These results suggest that the
lactone was hydrolyzed under basic reaction conditions to provide a
carboxylate/phenolate dianion intermediate that cyclized upon
acidiﬁcation.
(20) See ref 1, Supporting Information, p S4.
(21) (a) Hoﬀman, R.; Ozery, Y. Nitrogen NMR. http://chem.ch.huji.
ac.il/nmr/techniques/1d/row2/n.html#n (accessed Nov 20, 2014).
(b) Silverstein, R. M.; Webster, F. X.; Kiemle, D. J. Spectrometric
Identiﬁcation of Organic Compounds, 7th ed.; John Wiley & Sons:
Hoboken, NJ, 2005; pp 153−155.
(22) We acknowledge a reviewer for bringing this information to our
attention.

assay was performed in triplicate in 96-well microplates and consisted
of the following: 1 μL of compound in DMSO, 31 μL of factor XIa
buﬀer, 20 μL of factor XIa, followed by incubation at rt for 15 min.
Then, 20 μL of substrate S2366 (0.9 mM in FXIa assay buﬀer) was
added, followed by incubation for 2 h at rt. Absorbance was then read
at 405 nM. In-plate controls consisted of 0% inhibition (1 μL of
DMSO, 31 μL of buﬀer, 20 μL of factor XIa, and 20 μL of substrate
S2366) and 100% inhibition (1 μL of DMSO, 51 μL of buﬀer, 20 μL
of substrate S2366).
Data Analysis. Percent inhibition was calculated as follows:

%inhibition = 100 − {[(Abscompound − Abs100%inhibition )

■

/(Abs0%inhibition − Abs100%inhibition )] × 100}
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